Maternal Fecal Microbiota Transplantation in Cesarean-Born Infants Rapidly Restores Normal Gut Microbial Development: A Proof-of-Concept Study

Cell. 2020 Oct 15;183(2):324-334.e5. doi: 10.1016/j.cell.2020.08.047. Epub 2020 Oct 1.

Abstract

Infants born by vaginal delivery are colonized with maternal fecal microbes. Cesarean section (CS) birth disturbs mother-to-neonate transmission. In this study (NCT03568734), we evaluated whether disturbed intestinal microbiota development could be restored in term CS-born infants by postnatal, orally delivered fecal microbiota transplantation (FMT). We recruited 17 mothers, of whom seven were selected after careful screening. Their infants received a diluted fecal sample from their own mothers, taken 3 weeks prior to delivery. All seven infants had an uneventful clinical course during the 3-month follow-up and showed no adverse effects. The temporal development of the fecal microbiota composition of FMT-treated CS-born infants no longer resembled that of untreated CS-born infants but showed significant similarity to that of vaginally born infants. This proof-of-concept study demonstrates that the intestinal microbiota of CS-born infants can be restored postnatally by maternal FMT. However, this should only be done after careful clinical and microbiological screening.

Keywords: cesarean section; clinical trial; colonization; early-life health; fecal microbiota transplantation; maternal seeding; microbiota development; newborn; selective outgrowth; vertical transmission.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cesarean Section / adverse effects
  • Delivery, Obstetric
  • Fecal Microbiota Transplantation / methods*
  • Feces / microbiology*
  • Female
  • Gastrointestinal Microbiome / physiology*
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Microbiota / physiology
  • Mothers
  • Pregnancy
  • Proof of Concept Study
  • Vagina / microbiology

Associated data

  • ClinicalTrials.gov/NCT03568734